Zusammenfassung
Das Immunsystem und seine Steuerungsfunktionen sind von zentraler Bedeutung für die Entstehung und den Verlauf von Tumorerkrankungen. Zahlreiche Tumorvakzinen wurden zur Verstärkung des Immunsystems entwickelt, um Tumorerkrankungen wirksam zu verhindern oder zu bekämpfen. Mittels Tumorvakzinen der ersten Generation wurden vereinzelt ermutigende klinische Ergebnisse erzielt. Aktuelle Studien prüfen optimierte Tumorvakzinen sowie deren Kombination mit anderen Tumor-Immuntherapien.
Similar content being viewed by others
Literatur
Burg SH der van, Arens R, Ossendorp F et al (2016) Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer 16:219–233
Coulie PG, Van den Eynde BJ, van der Bruggen P et al (2014) Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer 14:135–146
Finn OJ (2018) The dawn of vaccines for cancer prevention. Nat Rev Immunol 18:183–194
Gouttefangeas C, Rammensee HG (2018) Personalized cancer vaccines: adjuvants are important, too. Cancer Immunol Immunother 67:1911–1918
Haen SP, Rammensee HG (2013) The repertoire of human tumor-associated epitopes – identification and selection of antigens and their application in clinical trials. Curr Opin Immunol 25:277–283
Hilf N, Kuttruff-Coqui S, Frenzel K et al (2018) Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. https://doi.org/10.1038/s41586-018-0810-y. [Epub ahead of print]
Hodi FS, O’Day SJ, McDermott DF (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711–723
Ilyas S, Yang JC (2015) Landscape of tumor antigens in T cell immunotherapy. J Immunol 195:5117–5122
Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422
Kenter GG, Welters MJ, Valentijn AR et al (2009) Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361:1838–1847
Melief CJ, van Hall T, Arens R et al (2015) Therapeutic cancer vaccines. J Clin Invest 125:3401–3412
Phetsouphanh C, Zaunders JJ, Kelleher AD (2015) Detecting antigen-specific T cell responses: from bulk populations to single cells. Int J Mol Sci 16:18878–11893
Romero P, Banchereau J, Bhardwaj N et al (2016) The human vaccines project: a roadmap for cancer vaccine development. Sci Transl Med 8:334ps9
Sahin U, Türeci Ö (2018) Personalized vaccines for cancer immunotherapy. Science 359:1355–1360
Sahin U, Derhovanessian E, Miller M et al (2017) Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547:222–226
Timmerman JM, Czerwinski DK, Davis TA et al (2002) Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99:1517–1526
Yee C, Riddell SR, Greenberg PD (2001) In vivo tracking of tumor-specific T cells. Curr Opin Immunol 13:141–146
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature
About this entry
Cite this entry
Herr, W., Brossart, P. (2021). Tumorvakzine. In: Schmoll, HJ. (eds) Kompendium Internistische Onkologie . Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-46764-0_56-1
Download citation
DOI: https://doi.org/10.1007/978-3-662-46764-0_56-1
Received:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-662-46764-0
Online ISBN: 978-3-662-46764-0
eBook Packages: Springer Referenz Medizin